Table 5.
Median of overall survival analysis of patients who only received intervention: (A) BCc1 nanomedicine or Placebo without chemotherapy. (B) Death percentage analysis of patients who only received intervention: BCc1 nanomedicine or Placebo without chemotherapy
| Group | Metastatic | Non-metastatic | ||
|---|---|---|---|---|
| Total number | BCc1(n = 19) | Placebo (n = 11) | BCc1(n = 18) | Placebo (n = 10) |
| (A) Median of overall survival analysis | ||||
| Median (days) | 174 | 52 | 442 | 454 |
| Std. error | 46.75 | 46.64 | 41.43 | 44.635 |
| Median 95% CI (lower) | 118.40 | 0 | 361 | 366 |
| Median 95% CI (upper) | 229.59 | 113.69 | 523 | 541 |
| P-value for test of equality of survival distributions | 0.042 | 0.053 | ||
| HR (BCc1/Placebo) |
0.500 | 0.324 | ||
| Stage (n) | ||||
| I | 0 | 0 | 3 | 1 |
| II | 0 | 0 | 3 | 4 |
| III | 0 | 0 | 8 | 3 |
| IIII | 19 | 11 | 0 | 0 |
| (B) Death rate analysis median of overall survival analysis | ||||
| Death rate (%) | 49 | 63 | 13 | 30 |
Test of equality of survival distributions for (Bcc1 an0d placebo groups) assay with Log Rank (Mantel-Cox)